Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
ProMIS Neurosciences Inc. - Common Shares
(NQ:
PMN
)
1.845
-0.155 (-7.75%)
Streaming Delayed Price
Updated: 3:20 PM EDT, May 17, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about ProMIS Neurosciences Inc. - Common Shares
< Previous
1
2
3
Next >
PMN Stock Earnings: ProMIS Neurosciences Beats EPS for Q1 2024
May 15, 2024
PMN stock results show that ProMIS Neurosciences beat analyst estimates for earnings per share the first quarter of 2024.
Via
InvestorPlace
ProMIS Neurosciences Announces First Quarter 2024 Financial Results and Recent Highlights
May 14, 2024
Top-line data from first-in-human Phase 1a clinical trial of PMN310 as a treatment for Alzheimer’s disease on track for mid-2024
From
ProMIS Neurosciences Inc.
Via
GlobeNewswire
ProMIS Neurosciences Publishes Study Highlighting Oligomer Selectivity and Benefit of Amyloid-Beta-Directed Antibodies
April 30, 2024
Study results support differentiation of PMN310 from other amyloid-beta-directed antibodies
From
ProMIS Neurosciences Inc.
Via
GlobeNewswire
Why Ultragenyx Pharmaceutical Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Monday's Mid-Day Session
April 15, 2024
Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) fell sharply during Monday’s session after the company revealed new data from the Phase 1/2 study of GTX-102 for Angelman syndrome, a genetic...
Via
Benzinga
Dow Jumps Over 300 Points; Goldman Sachs Posts Upbeat Earnings
April 15, 2024
U.S. stocks traded higher this morning, with the Dow Jones index gaining more than 300 points on Monday. The Dow traded up 0.89% to 38,321.05 while the NASDAQ rose 0.70% to 16,288.03. The S&P 500 also...
Via
Benzinga
Topics
Stocks
Exposures
US Equities
ProMIS Neurosciences Publishes in the Journal of Biological Chemistry on the Interaction Between Pathogenic Proteins as a Treatment Target for ALS
April 09, 2024
Study results support ProMIS’ TDP-43 misfolding-specific epitope as a potential therapeutic target for Amyotrophic Lateral Sclerosis (ALS)
From
ProMIS Neurosciences Inc.
Via
GlobeNewswire
ProMIS Neurosciences to Present in Upcoming Investor Conferences in April
April 04, 2024
From
ProMIS Neurosciences Inc.
Via
GlobeNewswire
PMN Stock Earnings: ProMIS Neurosciences Beats EPS for Q4 2023
April 01, 2024
PMN stock results show that ProMIS Neurosciences beat analyst estimates for earnings per share the fourth quarter of 2023.
Via
InvestorPlace
ProMIS Neurosciences Announces Full Year 2023 Financial Results and Recent Highlights
April 01, 2024
Top-line data from first-in-human Phase 1a clinical trial of PMN310 as a treatment for Alzheimer’s disease on track for mid-2024
From
ProMIS Neurosciences Inc.
Via
GlobeNewswire
ProMIS Neurosciences Strengthens Global Intellectual Property Portfolio
March 11, 2024
Adds Key U.S. and International Patent Allowances to Further Protect the Company’s Monoclonal Antibody Therapeutic for the Treatment of Alzheimer’s Disease
From
ProMIS Neurosciences Inc.
Via
GlobeNewswire
ProMIS Neurosciences to Present at the 2024 BIO CEO & Investor Conference
February 22, 2024
From
ProMIS Neurosciences Inc.
Via
GlobeNewswire
ProMIS Neurosciences Achieves Milestone in Development of Therapeutic Alpha-Synuclein Vaccine
January 22, 2024
Lead vaccine candidate selected for advancement against synucleinopathies including Multiple System Atrophy, Parkinson’s disease and Dementia with Lewy bodies
From
ProMIS Neurosciences Inc.
Via
GlobeNewswire
Why TransCode Therapeutics Shares Are Trading Lower By Over 24%? Here Are Other Stocks Moving In Friday's Mid-Day Session
January 19, 2024
Shares of TransCode Therapeutics, Inc. (NASDAQ: RNAZ) fell sharply during Friday’s session. TransCode Therapeutics priced a 5,942,623 share common stock offering at $1.22 per share. TransCode...
Via
Benzinga
ProMIS Neurosciences Issues Letter to Shareholders
January 08, 2024
From
ProMIS Neurosciences Inc.
Via
GlobeNewswire
ProMIS Neurosciences, Inc. Announces Leadership Transition
January 03, 2024
Appoints Neil Warma, Industry Leader and ProMIS Board Member, as Interim Chief Executive Officer
From
ProMIS Neurosciences Inc.
Via
GlobeNewswire
ProMIS Neurosciences Announces Publication on Novel Target for ALS
December 20, 2023
From
ProMIS Neurosciences Inc.
Via
GlobeNewswire
ProMIS Neurosciences Doses First Subjects in Phase 1a Clinical Trial of PMN310 to Treat Alzheimer’s Disease
November 20, 2023
Advances novel monoclonal antibody designed to be highly selective for toxic oligomers of amyloid-beta (Aβ) in first-in-human study
From
ProMIS Neurosciences Inc.
Via
GlobeNewswire
ProMIS Neurosciences Announces Third Quarter 2023 Financial Results and Recent Highlights
November 14, 2023
From
ProMIS Neurosciences Inc.
Via
GlobeNewswire
ProMIS Neurosciences Closes $20.4 Million Private Placement Financing
September 08, 2023
At-the-Market fundraise to support Company through several potentially value-creating milestones and beyond
From
ProMIS Neurosciences Inc.
Via
GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For October 3, 2023
October 03, 2023
Via
Benzinga
ProMIS Neurosciences to Present at the H.C. Wainwright 25th Annual Global Investment Conference
September 06, 2023
From
ProMIS Neurosciences Inc.
Via
GlobeNewswire
Crude Oil Falls; Dick's Sporting Goods Earnings Miss Views
August 22, 2023
U.S. stocks traded mostly lower toward the end of trading, with the Dow Jones falling over 100 points on Tuesday. The Dow traded down 0.39% to 34,330.87 while the NASDAQ rose 0.24% to 13,530.50. The...
Via
Benzinga
Topics
Earnings
Stocks
Exposures
Financial
Fossil Fuels
US Equities
Why ProMIS Neurosciences Shares Are Trading Higher By 33%; Here Are 20 Stocks Moving Premarket
August 22, 2023
Gainers Axcella Health Inc. (NASDAQ: AXLA) shares gained 65% to $0.2887 in pre-market trading after gaining 12% on Monday. The company recently posted a narrower-than-expected quarterly loss.
Via
Benzinga
Why Macy's Are Trading Lower By Around 11%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
August 22, 2023
Gainers Fulcrum Therapeutics, Inc. (NASDAQ: FULC) shares jumped 42.8% to $5.60 after the FDA lifted clinical hold on the company’s FTX-6058 for sickle cell disease.
Via
Benzinga
Exposures
Product Safety
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
August 22, 2023
We're starting off Tuesday with a breakdown of the biggest pre-market stock movers investors will want to keep an eye on!
Via
InvestorPlace
ProMIS Neurosciences Announces $20.4 Million Private Placement Financing
August 21, 2023
From
ProMIS Neurosciences Inc.
Via
GlobeNewswire
ProMIS Neurosciences Announces Second Quarter 2023 Financial Results and Recent Highlights
August 14, 2023
From
ProMIS Neurosciences Inc.
Via
GlobeNewswire
Why Biophytis Shares Are Trading Higher By 54%; Here Are 20 Stocks Moving Premarket
July 18, 2023
Gainers Biophytis S.A. (NASDAQ: BPTS) shares surged 53.9% to $3.31 in pre-market trading after the company signed a partnership with SEQENS to produce Sarconeos (BIO101) active compound, the company's...
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
July 18, 2023
It's time to start off trading for Tuesday with a breakdown of the biggest pre-market stock movers worth watching this morning.
Via
InvestorPlace
Crude Oil Falls; GreenPower Motor Company Shares Spike Higher
July 17, 2023
U.S. stocks traded higher toward the end of trading, with the Dow Jones gaining 0.25% on Monday. The Dow traded up 0.25% to 34,596.04 while the NASDAQ rose 0.92% to 14,243.64. The S&P 500, also rose,...
Via
Benzinga
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.